191 related articles for article (PubMed ID: 26359333)
1. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation.
Francis K; Yu C; Alvrtsyan H; Sander S; Ghosh S; Rao Y; Sanchez H; Matchar D
Curr Med Res Opin; 2015 Dec; 31(12):2189-95. PubMed ID: 26359333
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
[No Abstract] [Full Text] [Related]
6. Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin.
Fonseca E; Sander SD; Hess GP; Ghosh S
J Manag Care Spec Pharm; 2015 Nov; 21(11):1039-53. PubMed ID: 26521116
[TBL] [Abstract][Full Text] [Related]
7. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
8. Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants.
Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
Curr Med Res Opin; 2018 Feb; 34(2):285-295. PubMed ID: 29166800
[TBL] [Abstract][Full Text] [Related]
9. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
Song X; Gandhi P; Gilligan AM; Arora P; Wang C; Henriques C; Sander S; Smith DM
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):213-222. PubMed ID: 28649894
[TBL] [Abstract][Full Text] [Related]
10. Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin.
Gilligan AM; Franchino-Elder J; Song X; Wang C; Henriques C; Sainski-Nguyen A; Wilson K; Smith DM; Sander S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):203-212. PubMed ID: 30251553
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
J Med Econ; 2021; 24(1):550-562. PubMed ID: 33910464
[TBL] [Abstract][Full Text] [Related]
12. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Gilligan AM; Gandhi P; Song X; Wang C; Henriques C; Sander S; Smith DM
Am J Cardiovasc Drugs; 2017 Dec; 17(6):481-492. PubMed ID: 28795348
[TBL] [Abstract][Full Text] [Related]
13. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Curr Med Res Opin; 2014 Aug; 30(8):1521-8. PubMed ID: 24758611
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population.
Berger JS; Ashton V; Laliberté F; Germain G; Bookhart B; Lejeune D; Boudreau J; Lefebvre P; Weir MR
Adv Ther; 2023 Mar; 40(3):1224-1241. PubMed ID: 36658454
[TBL] [Abstract][Full Text] [Related]
15. Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study.
Chi NF; Wang Y; Chien LN; Chien SC; Ko Y
Med Care; 2018 May; 56(5):410-415. PubMed ID: 29578954
[TBL] [Abstract][Full Text] [Related]
16. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
17. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
18. Treatment Persistence and Discontinuation with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States.
Coleman CI; Tangirala M; Evers T
PLoS One; 2016; 11(6):e0157769. PubMed ID: 27327275
[TBL] [Abstract][Full Text] [Related]
19. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
20. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
